Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAICS | P22234 | 14/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21571663 | 0.92 | PAICS (0.37) | PAICSPTGDRCCR5KCNH2 | |
| SCHEMBL21571621 | 0.91 | PAICS (0.38) | PAICSPTGDR | |
| SCHEMBL20339045 | 0.91 | PAICS (0.38) | PAICSPTGDRCCR5KCNH2 | |
| SCHEMBL21571635 | 0.91 | PAICS (0.39) | PAICSPTGDRCCR5KCNH2ALDH1A1 | |
| SCHEMBL20339059 | 0.91 | PAICS (0.37) | PAICSPTGDRCCR5 | |
| SCHEMBL21571655 | 0.90 | PAICS (0.35) | PAICSPTGDRALDH1A1MAPTNPSR1 | |
| SCHEMBL20352151 | 0.86 | PAICS (0.42) | PAICSPTGDR | |
| SCHEMBL20339064 | 0.86 | PAICS (0.39) | PAICSPTGDRKCNH2 | |
| SCHEMBL21571640 | 0.85 | PAICS (0.42) | PAICS | |
| SCHEMBL21571642 | 0.85 | PAICS (0.45) | PAICSPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
| WO-2018122549-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352295-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | PAICS, CDK12, CDK13 | PAICS 1/4885PTGDR 316/4885CCR5 1516/4885 |
| US-10961233-B2 | Oxazole derivatives for use in the treatment of cancer | PAICS, CDK13, CDK12 | PAICS 1/4885PTGDR 261/4885CCR5 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.